(Total Views: 830)
Posted On: 01/27/2021 5:08:39 PM
Post# of 153802
Just read this from TI on YMB, good comparison to arrive at market cap.
"Anyone who has done their homework knows that the science supports a successful result and that a successful result could easily lead to $7-10 billion in sales this year as indicated by Dr. Pourhassan in previous Webcasts. With 700 million share on a fully diluted basis outstanding according to the last SEC filing disclosing this, that is at least $10/share revenue. And that is just for Covid severe/critical without long hauler approval or NASH or cancer etc. And the latest government expert reports indicate while we can control Covid pretty well with vaccines, it is not going away for years. So there will be plenty of demand for leronlimab for years to come.
Stocks are often valued at multiples of revenue. 5X would be conservative for a growth company like this. Using 5X would result in a $50/share valuation.
The day of reckoning is coming soon, most likely within the next 10-14 days. Longs stay strong! "
"Anyone who has done their homework knows that the science supports a successful result and that a successful result could easily lead to $7-10 billion in sales this year as indicated by Dr. Pourhassan in previous Webcasts. With 700 million share on a fully diluted basis outstanding according to the last SEC filing disclosing this, that is at least $10/share revenue. And that is just for Covid severe/critical without long hauler approval or NASH or cancer etc. And the latest government expert reports indicate while we can control Covid pretty well with vaccines, it is not going away for years. So there will be plenty of demand for leronlimab for years to come.
Stocks are often valued at multiples of revenue. 5X would be conservative for a growth company like this. Using 5X would result in a $50/share valuation.
The day of reckoning is coming soon, most likely within the next 10-14 days. Longs stay strong! "
(6)
(0)
